Compare RLX Technology Inc (RLX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Zoetis Inc — how do they compare? RLX Technology Inc trades at $2.03 (market cap $2.52B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 12.7× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (4.85%). Which is the better fit depends on your goals.
| RLX | ZTS | |
|---|---|---|
Market Cap | $2.52B | $31.95B |
Sector | Technology | Health |
52-Week High | $2.73 | $156.76 |
52-Week Low | $1.79 | $71.91 |
Enterprise Value | $1.15B | $39.24B |
Dividend Yield | 4.85% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX trades at $2.06, up 0.49% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q1 2026 revenue growth driven by international expansion, with 2025 revenue of $3.62B and net income of $921.87M. Recent news highlights the vaping industry's projected growth and RLX's cash-rich, debt-free balance sheet.
Outlook is mixed: strong fundamentals and industry tailwinds support growth, but recent EPS misses and a single analyst 'Hold' rating suggest caution. Key risks include regulatory scrutiny and execution challenges in global markets. The stock presents opportunity for long-term investors if expansion succeeds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
